Cinctive Capital Management LP Apellis Pharmaceuticals, Inc. Transaction History

Cinctive Capital Management LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$38.07 - $59.71 $109,679 - $172,024	2,881 Added 8.23%	37,875 $1.45 Million
Q1 2024 May 15, 2024	BUY	$55.39 - $72.47 $1.61 Million - $2.1 Million	29,046 Added 488.33%	34,994 $2.06 Million
Q4 2023 Feb 14, 2024	BUY	$37.14 - $64.82 $220,908 - $385,549	5,948 New	5,948 $356,000
Q2 2022 Aug 15, 2022	BUY	$35.07 - $59.21 $126,252 - $213,156	3,600 Added 12.83%	31,654 $1.43 Million
Q1 2022 May 16, 2022	BUY	$35.46 - $54.12 $17,800 - $27,168	502 Added 1.82%	28,054 $1.43 Million
Q4 2021 Feb 14, 2022	SELL	$30.74 - $49.16 $720,791 - $1.15 Million	-23,448 Reduced 45.98%	27,552 $1.3 Million
Q3 2021 Nov 15, 2021	BUY	$31.4 - $69.84 $1.6 Million - $3.56 Million	51,000 New	51,000 $1.68 Million

308

115M

3.85M

1.09M

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.64B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

Get notified when there are updates to the investment portfolio of Cinctive Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Cinctive Capital Management LP with notifications on news.